Happi C T, Gbotosho G O, Sowunmi A, Falade C O, Akinboye D O, Gerena L, Kyle D E, Milhous W, Wirth D F, Oduola A M J
Malaria Research Laboratories, Postgraduate Institute of Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Am J Trop Med Hyg. 2004 Jan;70(1):20-6.
Parasite genotyping by a polymerase chain reaction was used to distinguish recrudescent from newly acquired Plasmodium falciparum infections in 50 of 160 Nigerian children taking part in a chloroquine efficacy study in Ibadan, Nigeria. A finger prick blood sample was taken from each child before and after treatment to identify recrudescent parasites. By investigating allelic variation in three polymorphic antigen loci, merozoite surface protein-1 (MSP-1), MSP-2, and glutamate-rich protein (GLURP), we determined parasite diversity in the population and in the infected host. DNA from pretreatment and post-treatment samples from 47 of the 50 patients who failed therapy was successfully amplified by the PCR. The MSP-1, MSP-2, and GLURP genotypes in all samples showed extensive diversity, indicating polyclonal infections. The average number of clones per infection in pre-treatment sample was 2.5 with MSP-1, 4.9 with MSP-2, and 2 with GLURP. The extent of multiplicity decreased significantly (P = 0.016) in posttreatment samples. Multiplicity of infection and initial parasite density were not age dependent. Comparison of the variant alleles in pretreatment and post-treatment samples of each patient indicates that 26 of the 47 children had genuinely recrudescent disease. Conversely, post-treatment samples from five children showed completely new genotypes, indicating either a previously sequestered population of parasites or a newly acquired infection. Overall, this study has shown the diversity and complexity of P. falciparum population in Ibadan, Nigeria. The study has also shown the dynamics of P. falciparum infections in this population before and after chloroquine treatment in an area of high malaria transmission.
在尼日利亚伊巴丹进行的一项氯喹疗效研究中,160名尼日利亚儿童参与其中,通过聚合酶链反应对寄生虫进行基因分型,以区分50名儿童中复发的恶性疟原虫感染和新感染的病例。在治疗前后从每个儿童采集手指刺血样本,以鉴定复发的寄生虫。通过研究三个多态性抗原位点,即裂殖子表面蛋白-1(MSP-1)、MSP-2和富含谷氨酸蛋白(GLURP)的等位基因变异,我们确定了人群和受感染宿主中的寄生虫多样性。50例治疗失败患者中47例的治疗前和治疗后样本的DNA通过聚合酶链反应成功扩增。所有样本中的MSP-1、MSP-2和GLURP基因型均显示出广泛的多样性,表明是多克隆感染。治疗前样本中每次感染的克隆平均数,MSP-1为2.5个,MSP-2为4.9个,GLURP为2个。治疗后样本中感染的多样性显著降低(P = 0.016)。感染的多样性和初始寄生虫密度与年龄无关。对每位患者治疗前和治疗后样本中的变异等位基因进行比较表明,47名儿童中有26名患有真正的复发病例。相反,五名儿童的治疗后样本显示出全新的基因型,表明要么是先前隐匿的寄生虫群体,要么是新获得的感染。总体而言,本研究显示了尼日利亚伊巴丹恶性疟原虫群体的多样性和复杂性。该研究还显示了在疟疾高传播地区,该群体在氯喹治疗前后恶性疟原虫感染的动态变化。